Ziccum - Dry powder vaccines — the liberation of vaccination.

SET VACCINES FREE

We formulate vaccines as tough, thermostable dry powders that can be transported anywhere in the world, to every child in the world—with no Cold Chain required.
We’re setting vaccines free, join us.

LET’S CRACK THE COLD CHAIN

1-in-5 children worldwide fail to receive even basic vaccines, 1.5 million a year die from vaccine- preventable diseases: The Cold Chain, the global refrigerated supply system needed to transport standard vaccine solutions, simply isn’t delivering. Dry powder vaccines can change that.

PREPARED FOR PANDEMICS

From coronavirus to Ebola, pandemics are a constant risk. The WHO includes preparing for epidemics and expanding access to vaccines as top priorities for the coming decade (1). Dry powder vaccines can be both stored and transported with no refrigeration, then simply diluted back into liquid at the point of inoculation.

THE ZICCUM PLEDGE

We pledge to increase global vaccine coverage to 95% of newborn babies—from today’s 86%. The WHO, UNICEF, GAVI and more are all calling for new solutions to increase vaccine coverage. With collaborators like the Emerging Virus Unit in Marseille, our aim is to work with regional, national and global alliances on innovation in vaccine formulation and supply.

FROM GENTLENESS—STRENGTH

So how do we do it? Ziccum’s LaminarPace technology gently air-dries vaccines at room temperature, keeping the active ingredient intact. It has been used in over 10 years of Contract Research, drying over 100 different substances including peptides, antibodies and other viruses.

Dry powder vaccines — the liberation of vaccination

Ziccum is developing new dry-powder versions of the world’s most urgently- needed vaccines. These new, gently air-dried formulations can be transported easily and cost-effectively, with no costly cold storage or refrigeration required.

Set vaccines free

Vaccines are one of humanity’s greatest achievements. For centuries they have liberated us from disease, death and poverty. Yet today they are not reaching the people who need them most. We have made great strides in developing new vaccines, but how we formulate vaccines remains unchanged from how it was 50 years ago.

VACCINE FORMUALTION IS LIFE-OR-DEATH. Ziccum’s air-drying technology is a major new innovation in how vaccines are formulated, increasing vaccine coverage, reducing vaccine costs and finally putting vaccines within reach of every child in every community.

Vaccines have set us free—now it’s our turn to liberate them.
THE VALUE OF VACCCINES

Let’s crack the Cold Chain

What are the real costs of the global Cold Chain that supply’s today’s vaccines? 1-in-5 children worldwide still don’t receive even basic vaccines, and 1.5 million die every year from vaccine-preventable diseases (WHO). The complex chain of refrigerated facilities is struggling to cope with growing demand as population, poverty and temperatures increase.

NOT JUST A HUMAN COST EITHER. The WHO estimates that more than 50% of precious vaccines may be wasted globally every year because of temperature control, logistics and shipment-related issues. ¹ And overall vaccination costs were cut by a half in a WHO vaccination pilot project in Benin ² that delivered vaccines outside the Cold Chain at ambient temperatures up to +40°C.

Let’s save lives and resources—with dry powder vaccines.
CUTTING THE COST OF THE COLD CHAIN

Prepared for pandemics

Vaccines are the world’s most powerful tools to prevent pandemics. The need has never been more urgent. As temperatures rise new and ancient pathogens emerge and re-emerge on the planet. Global travel, urbanization, growing populations and food supply crammed into ever closer proximity—all potentially hothouse new epidemics and pandemics.

SAFE, COST-EFFECTIVE STOCKPILING It is vitally important for all our futures to develop vaccines at speed, as well as have the ability to stockpile and transport vaccines quickly.
Let’s save lives and resources—with dry powder vaccines.

PREPARED FOR PANDEMICS

The Ziccum Pledge

A collective challenge calls for a collective solution. We’re committed to working with regional, national and global organizations involved in immunization to make sure that not only can humanity make new vaccines—but it can deliver them too.

We aim to work closely with global health organisations, vaccine manufacturers, global and regional governments and healthcare systems so that our technology can transform the vaccine landscape for the benefit of all.

Our pledge is to work collectively with a wide range of partners to increase global vaccine coverage from today’s

86% of newborn babies to 95%.

Join us—let’s set vaccines free.

From gentleness—strength

So how do we do it? Conventional drying technologies freeze or bake chemical substances, at -80 °C or +80 °C. Ziccum’s LaminarPace technology air-dries vaccines at room temperature. This keeps the active ingredient intact.

DRY-POWDER ADENOVIRUS. LaminarPace has already been used in over ten years of Contract Research, during which it has successfully dried over 100 different substances including peptides, antibodies and other viruses. Our dry-powder version of Adenovirus, a key ingredient in many vaccines, stayed active at +40°C for over a month, outperforming the WHO’s CTC (Controlled Temperature Chain) classification that requires vaccines to tolerate temperatures of +40°C for a minimum of three days ³.

ZICCUM DRY-POWDER VACCINES: 5 need-to-knows

Ziccum develops vaccines as robust, temperature-stable dry powders, with the active ingredient still intact.
Ziccum’s dry-powder vaccines require no refrigeration or costly cold chain during transportation or storage.
Ziccum’s dry-powder version of Adenovirus stayed active at +40° C for over a month (the WHO’s CTC (Controlled Temperature Chain) classification requires vaccines to tolerate temperatures of +40° C for three days.)
Ziccum’s vaccine formulations can be transported as powders, then easily diluted back into liquids at the point of inoculation, significantly reducing the cost of vaccines.
Ziccum’s LaminarPace was first developed to micronize dry powders for aerosol testing, offering high potential for novel administration routes like inhaled vaccines

FORMULATE, INNOVATE, VACCINATE

^{1    https://apps.who.int/iris/bitstream/handle/10665/68463/WHO_VB_03.18.Rev.1_eng.pdf?sequence=1&isAllowed=y

2    https://www.who.int/immunization/newsroom/press/19_02_2014_meningitis_vaccine_outside_cold_chain/en

3    https://www.who.int/immunization/programmes_systems/policies_strategies/IPAC_statement_OCC_CTC_October_2016.pdf?ua=1}